How apoptosis and epithelial-to-mesenchymal transition are nested in EGFR inhibitors resistance in lung cancer
| Autor: | Elena Garelli, Hélène Blons, Antoine Legras, Karine Pallier, Audrey Didelot, Simon Garinet |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine business.industry medicine.drug_class Cancer medicine.disease Resistance mutation Tyrosine-kinase inhibitor respiratory tract diseases 03 medical and health sciences T790M 030104 developmental biology 0302 clinical medicine Apoptosis 030220 oncology & carcinogenesis medicine Cancer research Epithelial–mesenchymal transition Lung cancer business EGFR inhibitors |
| Zdroj: | Journal of Thoracic Disease. 11:47-49 |
| ISSN: | 2077-6624 2072-1439 |
| DOI: | 10.21037/jtd.2018.12.117 |
| Popis: | Non-small cell lung cancer (NSCLC) is today the first cancer worldwide and represents the first cause of cancer-related death. The identification of EGFR activating mutations and development of specific EGFR inhibitors (EGFRi) such as tyrosine kinase inhibitor (TKI) has changed the management of metastatic NSCLC. However, TKI resistance progressively appeared and EGFR secondary resistance mutation have been identified such as the most frequent T790M (1). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|